MedTrace Logo

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

NCT05766605 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-03-13

No results posted yet for this study

Summary

This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

Conditions

  • Hepatocellular Carcinoma Resectable

Interventions

DRUG

Oxaliplatin

130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

DRUG

Doxorubicin

20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

DRUG

Lobaplatin

50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

DRUG

Cisplatin

50 mg per square body surface area was used for monthly transhepatic arterial infusions.

DRUG

Oxaliplatin, Leucovorin, fluorouracil

Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial. infusions

DRUG

Lobaplatin, Raltitrexed

Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Sponsors & Collaborators

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Mingxin Pan, Prof. · Study Principal Investigator Southern Medical University, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2026-01-01
Completion
2026-01-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05766605 on ClinicalTrials.gov